Supplier News
Subscribe to Supplier News

The Lead

Novo Nordisk to Cease Distribution of Tresiba in Germany

July 1, 2015 3:59 pm | News | Comments

The decision to cease distribution of Tresiba in Germany has no implications for the other countries where the product is available. Read more...

Novartis to Try Novel Pricing Strategy for Heart Failure Drug

July 1, 2015 8:27 am | by Ryan Bushey, Associate Editor | Articles | Comments

The company is treading carefully in establishing the exact cost per pill. Read more...

Stiolto Respimat Now Available in the U.S. for COPD Treatment

June 30, 2015 11:52 am | News | Comments

Boehringer Ingelheim Pharmaceuticals, Inc. announced today that Stiolto Respimat (tiotropium...

FDA's New HCT/P Draft Guidance Document: What is Minimal Manipulation in 2015?

June 30, 2015 10:04 am | by Kelly L. Lightfoot, Esq., Fuerst Ittleman David & Joseph | Articles | Comments

The first step in assessing how a HCT/P will be regulated by the FDA, and whether the resulting...

View Sample

FREE Email Newsletter

Daily news and top headlines for drug research professionals

Regeneron's Retinal Vein Occlusion Treatment Receives Approval in Japan

June 30, 2015 8:39 am | News | Comments

This new indication includes macular edema secondary to branch retinal vein occlusion in addition to the previously-approved indication of macular edema secondary to central retinal vein occlusion. Read more...

CHMP Recommends EU Approval for Novartis' Multiple Myeloma Treatment

June 30, 2015 8:18 am | News | Comments

Multiple myeloma is a cancer of the plasma cells, a type of white blood cell present in the bone marrow, and affects approximately 84,000 people in Europe. Read more...

Novartis Acquires U.S. Biotech Firm Spinifex

June 29, 2015 8:45 am | by The Associated Press | News | Comments

Novartis didn't disclose financial details Monday of the agreement. Read more...


EU Recommends Approval of Roche's Pre-Surgery Breast Cancer Treatment

June 29, 2015 8:29 am | News | Comments

The majority of breast cancer cases are diagnosed at an early stage of the disease, before the cancer has spread to other parts of the body. Read more...

Allergan Layoffs Done at Irvine Location; Kythera Cuts in Question

June 26, 2015 1:35 pm | by Ryan Bushey, Associate Editor | Articles | Comments

The CEO of Allergan discussed the future of his company after the completion of the Actavis merger. Read more...

Global Gene Therapy Deals Sky-Rocketed to Nearly $5B in 2014

June 26, 2015 8:31 am | by Adam Dion, MS, Senior Industry Analyst, GlobalData | Articles | Comments

Nearly $1.5 billion was raised in the gene therapy arena from 2014 to 2015. Read more...

FDA Approves Eisai's Antiepileptic Agent Fycompa

June 24, 2015 8:46 am | News | Comments

It will be used as an adjunctive treatment for primary generalized tonic-clonic seizures. Read more...

BMS Will Win Big with Melanoma Combination Immunotherapy

June 24, 2015 8:39 am | by Fenix Leung, DPhil, Oncology and Hematology Analyst, GlobalData | Articles | Comments

Data presented at the recent American Society of Clinical Oncology Annual Meeting 2015 by Bristol-Myers Squibb suggests that its Opdivo/Yervoy combination of immunotherapies to treat metastatic melanoma will shape the therapeutic landscape once it is approved. Read more...  


Pharma R&D Pipeline Value Jumps 18 Percent to $493 Billion

June 23, 2015 12:36 pm | by Stephanie Guzowski, Editor | News | Comments

The pharmaceutical industry charges on across the U.S. and Europe, fueling a projected 5 percent increase in global prescription sales over the next five years, according to the industry report, “World Preview 2015, Outlook to 2020” from market intelligence firm, Evaluate. Read more...

Sandoz Announces U.S. Launch of Glatopa

June 22, 2015 4:25 pm | News | Comments

This is the first generic version of Teva's Copaxone. Read more...

Tekmira Says Ebola Drug Unlikely to Work in Study

June 22, 2015 8:21 am | by The Associated Press | News | Comments

The Canadian company said the mid-stage study reached a statistical futility boundary. Read more...

GlaxoSmithKline Invests $95M in Independent Genetics Institute

June 19, 2015 1:29 pm | by Seth Augenstein, Digital Reporter | News | Comments

GlaxoSmithKline is investing in probing deep into a human cell’s “operating system,” they announced this week. The London-based pharma company is investing $95 million in a new startup called the Altius Institute for Biomedical Sciences in Seattle, they announced. Read more...

MedDay Reports Additional Positive Data from Phase 3 Study of Progressive MS Drug

June 19, 2015 9:32 am | News | Comments

The data will be announced on Saturday June 20th at The 1st Congress of the European Academy of Neurology (EAN). Read more...


Lilly, Dana-Farber Cancer Institute Announce Research Collaboration

June 18, 2015 8:59 am | News | Comments

Eli Lilly and Company and Dana-Farber Cancer Institute announced a multiyear collaboration to research new medicines under development to fight cancer. Read more...

Kezar Life Sciences Closes $23M Series A Financing

June 17, 2015 1:39 pm | News | Comments

Kezar Life Sciences, a company focused on the discovery and development of drugs targeting protein homeostasis for autoimmune disorders, announced the completion of a Series A financing totaling $23 million. Read more...

Johns Hopkins University, Bayer to Develop New Ophthalmic Therapies

June 17, 2015 1:03 pm | by Johns Hopkins University | News | Comments

The Johns Hopkins University and Bayer HealthCare have entered into a five-year collaboration agreement to jointly develop new ophthalmic therapies targeting retinal diseases. The goal of the strategic research alliance is to accelerate the translation of innovative approaches from the laboratory to the clinic, ultimately offering patients new treatment options for several retinal diseases. Read more...

Bert Vogelstein, M.D., Wins 2015 Dr. Paul Janssen Award for Biomedical Research

June 17, 2015 12:58 pm | News | Comments

Johnson & Johnson today named Dr. Bert Vogelstein of Johns Hopkins University, Johns Hopkins Kimmel Cancer Center and the Howard Hughes Medical Institute, the winner of the 2015 Dr. Paul Janssen Award for Biomedical Research for his breakthroughs in oncology research, which have spanned more than two decades and have formed the basis of modern cancer research. Read more...

Genticel Receives FDA Clearance of IND Application to Conduct Phase 1 Clinical of GLT001

June 17, 2015 8:58 am | News | Comments

The trial will take place in the United States. Read more...

Richter, Allergan Announce FDA Extended Review Period for Cariprazine to September 2015

June 17, 2015 8:47 am | News | Comments

Cariprazine is being reviewed for the treatment of schizophrenia and for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults. Read more...

Avalon Ventures, GSK Launch Three New Companies

June 16, 2015 10:54 am | News | Comments

Avalon Ventures today announced the launch of three new companies formed through its ongoing successful collaboration with GSK to fund and launch up to 10 early-stage life science companies. Read more..

MERS Not Given Same Vaccine Attention as Ebola, Other Viruses

June 16, 2015 8:50 am | by Seth Augenstein, Digital Reporter | Articles | Comments

Authorities are scrambling to control the spread of the illness, known fully as the Middle East Respiratory Syndrome. Read more...

Actavis Begins Operating as Allergan

June 15, 2015 3:10 pm | News | Comments

Allergan has initiated a rebranding campaign that will guide the transition of its facilities, operations and commercial presence around the world to the new company name. Read more...

EULAR 2015: Roche Gains Breakthrough Designation for Systemic Sclerosis Drug

June 11, 2015 8:55 am | News | Comments

Roche also initiated a global Phase 3 study in SSc. Read more...

Mylan Launches First Bioequivalent Alternative to Serotide Evohaler in U.K.

June 10, 2015 8:17 am | News | Comments

It will be sold under the brand name Sirdupla. Read more...

Glaucoma Treatment Market Value Will Grow Moderately to $3B by 2023

June 10, 2015 8:16 am | by Catherine Daly, Ph.D., Senior Neurology and Ophthalmology Analyst, GlobalData | Articles | Comments

Sales for glaucoma treatment will remain relatively flat until 2016, followed by a period of sustained growth due to the arrival of pipeline drugs. Read more...

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.